EUCTR2006-000389-35-DK进行中（未招募）不适用
A Nordic phase II study of peripheral T-cell lymphomas based on dose-intensive induction and high-dose consolidation with autologous stem cell rescue - NLG-T-01
ordic Lymphoma Group0 个研究点目标入组 120 人开始时间: 2006年5月16日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Previously untreated patients with newly diagnosed peripheral T-cell lymphoma of all stages
- •Following histologic subtypes( WHO classification are eligible for inclusion in the study: Peripheral T-Cell lymphoma, Angioimmunoblastic T-Cell lymphoma, NK/T nasal type t_cell lymphoma, Enteropaty type T-cell lymphoma, Primary systemic alk-negative anaplastic large cell lymphoma( T-or null phenotype)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Primary cutanous T-or null-cell anaplastic large cell lymphoma
- •alk positive, primary systemic T-or null cell anaplastic large cell lymphoma
- •Whp performance status grade 4
- •Patients with severe cardiac, pulmonary, neurologic,psychiatric, renal, hepatic or metabolic disease.
研究者
相似试验
已完成
2 期
A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCTPeripheral T-Cell LymphomaNCT00791947University of Aarhus166
已完成
不适用
A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell LymphomasLymphoma, T-Cell, PeripheralNCT02788916Takeda198
终止
2 期
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's LymphomaLymphomaNCT00810576M.D. Anderson Cancer Center1
已完成
2 期
Multicenter phase I/IIa study using T-cell receptor gene therapy in metastatic melanomamaligne melanomauveal melanoma1003005410040900skin cancerNL-OMON47165ederlands Kanker Instituut20
进行中（未招募）
1 期
A phase 2 bridging study to assess that the new formulation of ETVAX is not inferior to the previous formulatioHealthy volunteers (prevention of diarrheal disease due to infection with enterotoxigenic E. coli [ETEC])MedDRA version: 21.1Level: LLTClassification code 10054983Term: Prophylaxis against traveller's diarrheaSystem Organ Class: 100000004865MedDRA version: 20.1Level: LLTClassification code 10022665Term: Intestinal infection due to enterotoxigenic E. coliSystem Organ Class: 100000004862EUCTR2021-001541-13-SEScandinavian Biopharma Holding AB280